TDP-43 Co-pathology in Corticobasal Syndrome

TDP-43 Co-pathology in Corticobasal Syndrome

Overview

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS[@murakami2025].

TDP-43 (TAR DNA-binding protein 43) is a 414-amino acid nuclear protein encoded by the [TARDBP](/genes/tardbp) gene that plays critical roles in RNA splicing, transport, and stability. In neurodegenerative diseases, TDP-43 undergoes pathological transformation characterized by phosphorylation, ubiquitination, cleavage into C-terminal fragments, and aggregation into cytoplasmic inclusions. This page comprehensively covers TDP-43 co-pathology mechanisms in CBS.

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

| Pathological Category | Percentage of CBS Cases |
|---------------------|------------------------|
| Pure 4R tauopathy (no TDP-43) | ~50-60% |
| Mixed tau + TDP-43 pathology | ~25-35% |
| TDP-43 predominant | ~10-15% |

TDP-43 Co-pathology in Corticobasal Syndrome

Overview

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS[@murakami2025].

TDP-43 (TAR DNA-binding protein 43) is a 414-amino acid nuclear protein encoded by the [TARDBP](/genes/tardbp) gene that plays critical roles in RNA splicing, transport, and stability. In neurodegenerative diseases, TDP-43 undergoes pathological transformation characterized by phosphorylation, ubiquitination, cleavage into C-terminal fragments, and aggregation into cytoplasmic inclusions. This page comprehensively covers TDP-43 co-pathology mechanisms in CBS.

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

| Pathological Category | Percentage of CBS Cases |
|---------------------|------------------------|
| Pure 4R tauopathy (no TDP-43) | ~50-60% |
| Mixed tau + TDP-43 pathology | ~25-35% |
| TDP-43 predominant | ~10-15% |

The distribution of TDP-43 pathology in CBS includes:

• Motor cortex (especially layer II)
• Basal ganglia (putamen, globus pallidus)
• Substantia nigra
• Hippocampus (in cases with cognitive impairment)
• Spinal cord anterior horns

Clinical Correlations

The presence of TDP-43 pathology influences the clinical presentation of CBS[@murakami2025]:

Mechanisms of TDP-43 Pathology in CBS

Pathological Mechanisms

The mechanisms linking TDP-43 pathology to CBS include:

Genetic Contributions

Several genetic factors influence TDP-43 pathology in CBS:

• GRN (Progranulin) Mutations: Associated with increased TDP-43 pathology
• C9orf72 Expansions: Can present with CBS phenotype with TDP-43 pathology
• TMEM106B Variants: Modify TDP-43 pathology risk

TDP-43 Inclusion Types in CBS

The pathological manifestations of TDP-43 in CBS are heterogeneous and include multiple inclusion types:

1. Cytoplasmic Inclusions

| Inclusion Type | Description | Prevalence in CBS |
|---------------|-------------|-------------------|
| Lewy body-like inclusions | Spherical, eosinophilic cytoplasmic inclusions | ~40% of TDP-43+ cases |
| Compact inclusions | Dense, round inclusions without halo | ~25% of TDP-43+ cases |
| Grains and pretangles | Fine, thread-like structures | ~20% of TDP-43+ cases |
| Perivascular inclusions | Inclusions surrounding blood vessels | ~15% of TDP-43+ cases |

2. Neuronal Inclusions

• Neuronal cytoplasmic inclusions (NCIs): Most common type, found in pyramidal neurons
• Neuronal intranuclear inclusions (NIIs): Less common, associated with specific genetic forms
• Dystrophic neurites: Abnormal neuritic processes containing TDP-43

3. Glial Inclusions

• Astrocytic inclusions: TDP-43 positive astrocytes in affected regions
• Oligodendroglial inclusions: Less frequently observed

4. Morphological Variants

The morphology of TDP-43 inclusions in CBS differs from classical ALS/FTD patterns:

• More diffuse cytoplasmic staining
• Less prominent skein-like inclusions compared to ALS
• More frequent co-localization with tau pathology

Relationship Between Tau and TDP-43 Pathology

Bidirectional Interaction Mechanisms

The relationship between tau and TDP-43 in CBS is complex and involves multiple interaction pathways:

Mechanisms of Tau-TDP-43 Co-aggregation

Regional Distribution Patterns

The anatomical distribution of tau and TDP-43 pathology often shows complementary patterns:

| Brain Region | Primary Pathology | Secondary Pathology |
|-------------|------------------|-------------------|
| Motor cortex | Tau > TDP-43 | TDP-43 in layers II/III |
| Basal ganglia | Tau predominant | TDP-43 in striatum |
| Substantia nigra | Both common | Variable dominance |
| Hippocampus | TDP-43 predominant | Tau in CA1/Subiculum |

TDP-43 Aggregation Mechanisms

Molecular Pathways to Aggregation

1. Nuclear Clearance and Cytoplasmic Mislocalization

TDP-43 normally resides in the nucleus but in disease states accumulates in the cytoplasm. Key mechanisms include:

• Nuclear import defects: Reduced importin-α/β function
• Nuclear export dysregulation: Enhanced CRM1-mediated export
• Stress granule formation: TDP-43 seeded into stress granules

2. Post-translational Modifications

| Modification | Effect on TDP-43 | Detection in CBS |
|-------------|-----------------|------------------|
| Phosphorylation at Ser409/410 | Promotes aggregation | ~80% of inclusions |
| Ubiquitination | Marks for degradation | ~90% of inclusions |
| C-terminal cleavage | Generates aggregation-prone fragments | ~70% of cases |
| Acetylation | Impairs RNA binding | Associated with stress |

3. Cryo-EM Structures

Recent cryo-EM studies have elucidated TDP-43 filament structures in CBS and related disorders [@arseni2022]:

• Type A filaments: Left-handed helical filaments, 10-12 nm diameter
• Type B filaments: Right-handed helical filaments, 10-15 nm diameter
• Core structure: Residues 274-331 form the filament core
• Phosphorylation: Ser409/410 in the disordered outer shell

Aggregation Kinetics

Comparison with ALS/FTD TDP-43 Pathology

Shared Features

| Feature | CBS | ALS | FTD |
|---------|-----|-----|-----|
| Phosphorylated TDP-43 | ✓ | ✓ | ✓ |
| Ubiquitin positive | ✓ | ✓ | ✓ |
| C-terminal fragments | ✓ | ✓ | ✓ |
| Nuclear clearing | ✓ | ✓ | ✓ |

Distinctive Features in CBS

Pathological Staging

| Stage | ALS Pattern | CBS Pattern |
|-------|-------------|--------------|
| Early | Motor cortex | Motor cortex + basal ganglia |
| Middle | Brainstem + spinal cord | Substantia nigra + limbic |
| Late | Diffuse involvement | Hippocampal + frontal involvement |

Impact on Neuronal Dysfunction

Mechanisms of TDP-43-Mediated Neurotoxicity

1. Loss of Nuclear Function

• Impaired RNA splicing (exon skipping, intron retention)
• Disrupted RNA transport and localization
• Altered gene expression programs

2. Gain of Cytoplasmic Function

• Stress granule pathology
• Translation dysregulation
• Mitochondrial dysfunction
• Axonal transport defects

3. Cellular Vulnerability Factors

| Factor | Contribution |
|--------|-------------|
| Neuronal size | Large neurons more vulnerable |
| Metabolic demand | High energy requiring neurons |
| Axonal length | Long projection neurons |
| Calcium dysregulation | Excitotoxicity amplification |

Clinical Manifestations

The presence of TDP-43 pathology in CBS correlates with:

Genetic Factors Modifying TDP-43 in CBS

Major Genetic Contributors

GRN (Progranulin)

[GRN](/genes/grn) mutations cause haploinsufficiency leading to reduced progranulin levels[@baker2006]:

• Mechanism: Progranulin deficiency impairs lysosomal function
• Result: TDP-43 accumulates due to impaired clearance
• Pathology: Type A TDP-43 inclusions

C9orf72 Repeat Expansions

[C9orf72](/genes/c9orf72) hexanucleotide repeat expansions[@dejesushernandez2011]:

• Mechanism: RNA foci formation and dipeptide repeat proteins
• Result: TDP-43 pathology as downstream effect
• Pathology: Type B TDP-43 inclusions

TMEM106B Variants

[TMEM106B](/genes/tmem106b) acts as a modifier[@van2010]:

• Risk variant: TMEM106B haplotypes affect lysosomal function
• Effect: Modulates TDP-43 pathology severity
• Interaction: Effects modified by GRN status

TDP-43 Classification Systems

Biomarker-Based Classification

A 2025 study by Palleis et al. established a biomarker-based classification system for CBS that incorporates TDP-43 pathology[@palleis2025]:

| Biomarker Profile | Underlying Pathology | Prevalence |
|------------------|---------------------|------------|
| Tau-positive, TDP-43 negative | Primary 4R tauopathy | ~55% |
| Tau-positive, TDP-43 positive | Mixed tau + TDP-43 | ~30% |
| TDP-43 positive, tau negative | Primary TDP-43opathy | ~15% |

This classification has diagnostic and prognostic implications.

Diagnostic Implications

Clinical-Pathological Correlations

Understanding TDP-43 pathology in CBS has practical implications:

Biomarkers for TDP-43 Pathology

Current and emerging biomarkers include:

• Neurofilament Light Chain (NfL): Elevated in CSF and blood; higher levels in TDP-43 cases
• TDP-43 CSF Levels: Under investigation as direct marker
• PET Tracers: Emerging tau PET may help differentiate pathologies

Therapeutic Implications

Targeting TDP-43 Pathology

Therapeutic strategies for TDP-43 in CBS include[@progranulin]:

Progranulin-Based Therapies

Given the association between GRN mutations and TDP-43 pathology[@progranulina]:

• Recombinant Progranulin: Currently in clinical trials for FTD-GRN
• Gene Therapy: AAV-mediated PGRN delivery under investigation
• Small Molecule Enhancers: Compounds that increase progranulin expression

Relationship to Other CBS Mechanisms

• [LRRK2 in CBS and 4R Tauopathies](/mechanisms/lrrk2-cbs-tauopathies) — Shared mechanisms with other 4R tauopathies
• [CBS vs PSP: Comparative Mechanism Analysis](/mechanisms/cbs-vs-psp-comparison) — TDP-43 frequency differences
• [GRN — Progranulin](/genes/grn) — Genetic factors in TDP-43 pathology
• [C9orf72](/genes/c9orf72) — Hexanucleotide repeat expansions with TDP-43 pathology
• [TARDBP](/genes/tardbp) — TDP-43 encoding gene
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — General TDP-43 mechanisms
• [Progranulin Therapy](/therapeutics/progranulin-therapy) — Therapeutic approaches

Summary

TDP-43 pathology is present in a substantial minority of CBS cases, influencing clinical presentation, disease progression, and therapeutic approaches. The 2025 research by Murakami et al. and others has clarified that:

Understanding the TDP-43 component of CBS is essential for precision medicine approaches to this heterogeneous disorder.

See Also

• [TARDBP](/genes/tardbp)
• [GRN](/genes/grn)
• [C9orf72](/genes/c9orf72)
• [TMEM106B](/genes/tmem106b)
• [LRRK2 in CBS and 4R Tauopathies](/mechanisms/lrrk2-cbs-tauopathies)
• [CBS vs PSP: Comparative Mechanism Analysis](/mechanisms/cbs-vs-psp-comparison)
• [GRN — Progranulin](/genes/grn)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Progranulin Therapy](/therapeutics/progranulin-therapy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References